SAN DIEGO, May 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.
The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Media/Investor Contact: Anne Erickson Executive Director Halozyme Therapeutics 858-704-8264 firstname.lastname@example.org
SOURCE Halozyme Therapeutics, Inc.